These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 6869318)

  • 1. Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with upper gastrointestinal tumors. A preliminary report.
    Bedikian AY; Stroehlein J; Korinek J; Karlin D; Valdivieso M; Bodey GP
    Am J Clin Oncol; 1983 Aug; 6(4):473-6. PubMed ID: 6869318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with metastatic colorectal cancer.
    Bedikian AY; Stroehlein J; Korinek J; Karlin D; Valdivieso M; Bodey GP
    Am J Clin Oncol; 1983 Feb; 6(1):45-8. PubMed ID: 6837506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma.
    Arseneau JC; Schoenfeld DA; Borden EC
    Invest New Drugs; 1986; 4(1):53-6. PubMed ID: 3700041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical evaluation of dihydroxyanthracenedione in patients with advanced lung cancer.
    Valdivieso M; Umsawasdi T; Spitzer G; Chiuten DF; Booser DJ; Dhingra HM; Bodey GP
    Am J Clin Oncol; 1984 Jun; 7(3):241-4. PubMed ID: 6328968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II studies of mitoxantrone in patients with primary liver cancer.
    Falkson G; Coetzer BJ
    Invest New Drugs; 1985; 3(2):187-9. PubMed ID: 4019121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of mitoxantrone on a daily X 5 schedule.
    Goldsmith MA; Ohnuma T; Jaffrey IH; Greenspan EM; Holland JF
    Am J Clin Oncol; 1984 Oct; 7(5):567-70. PubMed ID: 6507380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitoxantrone in advanced breast cancer: a phase II trial of the Southwest Oncology Group.
    Knight WA; Von Hoff DD; Neidhart JA; Tranum BL; Fabian C; Jones SE
    Invest New Drugs; 1983; 1(2):181-4. PubMed ID: 6678866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of a 5-day schedule of mitoxantrone (dihydroxyanthracenedione).
    Wynert WR; Harvey HA; Lipton A; Schweitzer J; White DS
    Cancer Treat Rep; 1982 Jun; 66(6):1303-6. PubMed ID: 7083234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical evaluation of AZQ in colorectal cancer.
    Bedikian AY; Stroehlein JR; Karlin DA; Korinek J; Bodey GP
    Am J Clin Oncol; 1982 Oct; 5(5):535-7. PubMed ID: 7180831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino 9,10-anthracenedione dihydrochloride)(NSC 301739, DHAD) in patients with metastatic malignant melanoma. A Southwest Oncology Group pilot.
    Taylor SA; Tranum BT; Von Hoff DD; Costanzi JJ
    Invest New Drugs; 1985; 3(1):67-9. PubMed ID: 3988458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II evaluation of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU, NSC 95466) in patients with metastatic colorectal cancer.
    Bedikian AY; Stroehlein JR; Karlin DA; Bennetts RW; Stewart DJ; Bodey GP
    Am J Clin Oncol; 1983 Feb; 6(1):49-52. PubMed ID: 6837507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II evaluation of aclacinomycin A (ACM-A, NSC208734) in patients with metastatic colorectal cancer.
    Bedikian AY; Stroehlein J; Korinek J; Karlin D; Valdivieso M; Bodey G
    Am J Clin Oncol; 1983 Apr; 6(2):187-90. PubMed ID: 6572470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical study of dihydroxyanthracenedione administered on a 5-day iv schedule.
    Valdivieso M; Bedikian AY; Burgess MA; Savaraj N; Jeffers WB; Bodey GP
    Cancer Treat Rep; 1981; 65(9-10):841-4. PubMed ID: 7273017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas].
    Kimura I; Ohnoshi T; Ogawa M; Sampi K; Masaoka T; Yamada K; Ohta K; Kitani T; Kawagoe H; Shirakawa S
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2800-6. PubMed ID: 3753026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study.
    Mouridsen HT; Cornbleet M; Stuart-Harris R; Smith I; Coleman R; Rubens R; McDonald M; Rainer H; van Oosterom A; Smyth J
    Invest New Drugs; 1985; 3(2):139-48. PubMed ID: 4019118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An EORTC phase II study of mitoxantrone in solid tumors and lymphomas.
    De Jager R; Cappelaere P; Armand JP; Keiling R; Fargeot P; Bastit P; van Glabbeke M; Renard J; Earl H; Rubens R
    Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1369-75. PubMed ID: 6542006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and clinical pharmacologic studies of mitoxantrone.
    Stewart JA; McCormack JJ; Krakoff IH
    Cancer Treat Rep; 1982 Jun; 66(6):1327-31. PubMed ID: 7083236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer.
    Osborne CK; Drelichman A; Von Hoff DD; Crawford ED
    Cancer Treat Rep; 1983 Dec; 67(12):1133-5. PubMed ID: 6652630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients.
    Cornbleet MA; Stuart-Harris RC; Smith IE; Coleman RE; Rubens RD; McDonald M; Mouridsen HT; Rainer H; van Oosterom AT; Smyth JF
    Eur J Cancer Clin Oncol; 1984 Sep; 20(9):1141-6. PubMed ID: 6541135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitoxantrone in malignant lymphoma.
    Gams RA; Bryan S; Dukart G; Weiss A; Case D; Jones S; Stein R
    Invest New Drugs; 1985; 3(2):219-22. PubMed ID: 4019123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.